JAGX
Jaguar Health, Inc. NASDAQ Listed May 12, 2015$0.88
After hrs
$0.88
-0.18%
Mkt Cap $58.6K
52w Low $0.76
0.1% of range
52w High $81.55
50d MA $1.87
200d MA $20.09
P/E (TTM)
0.0x
EV/EBITDA
—
P/B
—
Debt/Equity
-2.5x
ROE
-248.6%
P/FCF
0.0x
RSI (14)
43.80
ATR (14)
$0.10
Beta
0.29
50d MA
$1.87
200d MA
$20.09
Avg Volume
136.0K
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
200 Pine Street · San Francisco, CA 94104 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 20, 2026 | AMC | -71.40 | -13.60 | +81.0% | 3.67 | -15.5% | -5.4% | -16.1% | +6.9% | +2.6% | +3.1% | — |
| May 18, 2026 | AMC | -1.49 | -3.14 | -110.6% | 3.70 | -1.1% | -9.2% | +9.2% | -5.4% | -16.1% | +6.9% | — |
| May 15, 2026 | AMC | -1.49 | -3.14 | -110.6% | 3.92 | +1.5% | -5.6% | -9.2% | +9.2% | -5.4% | -16.1% | — |
| Apr 7, 2026 | AMC | -1.49 | -3.14 | -110.6% | 14.33 | +5.3% | -2.5% | -5.0% | -2.6% | +5.7% | +4.1% | — |
| Mar 30, 2026 | AMC | -71.40 | -13.60 | +81.0% | 11.66 | +4.2% | +11.2% | +9.6% | -1.5% | +2.5% | -0.1% | — |
| Nov 14, 2025 | AMC | -5.08 | -6.28 | -23.6% | 62.30 | -0.6% | +1.7% | -8.3% | -18.7% | -8.1% | -2.4% | — |
| Nov 12, 2025 | AMC | -1.78 | -2.20 | -23.6% | 61.25 | -1.1% | -2.9% | +4.7% | +1.7% | -8.3% | -18.7% | — |
| Aug 14, 2025 | AMC | -2.50 | -3.59 | -43.8% | 72.45 | +2.4% | +1.4% | -1.4% | -7.2% | -2.6% | -2.7% | — |
| May 15, 2025 | AMC | -3.79 | -5.84 | -54.3% | 192.50 | +1.1% | +6.9% | -2.0% | +1.4% | -27.1% | +6.3% | — |
| Mar 31, 2025 | AMC | -6.47 | -5.15 | +20.4% | 166.60 | +3.2% | +0.0% | -1.9% | -2.6% | -4.0% | +9.6% | — |
| Nov 13, 2024 | AMC | -2.37 | -1.05 | +55.7% | 864.15 | +0.0% | +5.3% | -7.7% | +2.0% | -1.0% | +1.1% | — |
| Aug 13, 2024 | AMC | -1.20 | -4.04 | -236.7% | 936.25 | -0.9% | +0.0% | +10.3% | +7.6% | -2.4% | -4.8% | — |
| May 14, 2024 | AMC | -0.03 | -0.07 | -133.3% | 4812.50 | -0.2% | -7.3% | +12.4% | -9.8% | -34.8% | -15.4% | — |
| Apr 1, 2024 | AMC | -14.70 | -21.00 | -42.9% | 1347.50 | -4.5% | -3.9% | +0.0% | +4.7% | +8.4% | -2.4% | — |
| Nov 13, 2023 | AMC | -1.23 | -0.55 | +55.3% | 5425.00 | +6.5% | +6.9% | +15.1% | -4.3% | +11.4% | +13.7% | — |
| Aug 14, 2023 | AMC | -1.53 | -0.69 | +54.9% | 9362.50 | +0.9% | -4.7% | -0.8% | -1.2% | +0.0% | -5.8% | — |
| May 15, 2023 | AMC | -67.50 | -35.99 | +46.7% | 13273.75 | -1.8% | -11.7% | +1.6% | +0.0% | -2.4% | +5.2% | — |
| Mar 27, 2023 | BMO | -5.85 | -7.09 | -21.2% | 18200.00 | -3.8% | -25.0% | -5.6% | -4.8% | -10.5% | -6.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 7 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | — | — | — | — | — | — | — | — |
| Nov 25 | Aegis Capital | Maintains | Buy → Buy | — | $837200.00 | $840743.75 | +0.4% | -1.6% | +0.4% | +66.6% | +30.9% | -10.8% |
| Nov 25 | H.C. Wainwright | Maintains | Buy → Buy | — | $837200.00 | $840743.75 | +0.4% | -1.6% | +0.4% | +66.6% | +30.9% | -10.8% |
| Nov 25 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $837200.00 | $840743.75 | +0.4% | -1.6% | +0.4% | +66.6% | +30.9% | -10.8% |
| Nov 25 | Rodman & Renshaw | Maintains | Buy → Buy | — | $837200.00 | $840743.75 | +0.4% | -1.6% | +0.4% | +66.6% | +30.9% | -10.8% |
| Nov 18 | H.C. Wainwright | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Sep 12 | Ladenburg Thalmann | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Jul 11 | Rodman & Renshaw | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Nov 12 | Aegis Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
No insider trades available.
8-K
Jaguar Health, Inc. -- 8-K Filing
Jul 1
8-K
Jaguar Health, Inc. -- 8-K Filing
Jun 25
8-K · 7.01
! Medium
Jaguar Health, Inc. -- 8-K 7.01: Regulation FD Disclosure
Jun 22
8-K
Jaguar Health, Inc. -- 8-K Filing
Jun 11
8-K
Jaguar Health, Inc. -- 8-K Filing
Jaguar Health faces a one-year mandatory panel monitor requirement and has until September 2026 to regain listing compliance, indicating potential delisting risk if standards aren't met.
May 27
NT 10-Q
!! High
Jaguar Health, Inc. -- Late Quarterly Report -- Distress Signal
May 18
8-K
Jaguar Health, Inc. -- 8-K Filing
Jaguar Health received a Nasdaq compliance notice and must restore its stock price above $1.00 for ten consecutive trading days to maintain listing eligibility.
May 4
8-K · 5.03
! Medium
Jaguar Health, Inc. -- 8-K 5.03: Amendment to Articles / Bylaws
Jaguar Health amended its articles or bylaws, though the specific changes aren't detailed in this summary, potentially affecting shareholder rights or corporate governance structure.
Apr 27
8-K
Jaguar Health, Inc. -- 8-K Filing
Jaguar Health stockholders approved all five proposals at their April 20, 2026 special meeting, enabling the company to proceed with its strategic initiatives.
Apr 21
8-K
Unknown — 8-K Filing
The filing's emphasis on forward-looking statements about stockholders' equity exceeding $2.5 million suggests JAGX completed a significant transaction, potentially a merger or financing, which investors should monitor for dilution impacts and actual financial results.
Apr 9
8-K
Unknown — 8-K Filing
Jaguar Health's modest 5% sequential revenue growth coupled with $16M non-dilutive funding suggests stabilizing operations and reduced near-term dilution risk, though investors should monitor whether revenue acceleration materializes.
Apr 7
NT 10-K
!!! Very High
Unknown — Late Annual Report — Distress Signal
JAGX's late annual report filing signals potential financial or operational distress, making the stock riskier as investors lack timely disclosure and regulators may impose penalties or delisting consequences.
Apr 1
8-K · 1.01
!! High
Jaguar Health, Inc. -- 8-K 1.01: Material Agreement
Jaguar Health secured a $12 million agreement with Napo Pharmaceuticals, potentially strengthening its product portfolio and financial position through this strategic partnership or acquisition.
Mar 9
8-K
Jaguar Health, Inc. -- 8-K Filing
Jaguar Health faces potential delisting from Nasdaq after failing to maintain compliance standards, with no guarantee that its appeal to regain listing status will succeed.
Mar 6
8-K
Jaguar Health, Inc. -- 8-K Filing
Jaguar Health issued Series O Preferred Stock with conversion rights allowing shareholders to receive Common Stock upon conversion and participate in liquidation events, potentially diluting existing equity holders.
Mar 3
8-K · 8.01
!! High
Jaguar Health, Inc. -- 8-K 8.01: Material Event / Announcement
Jaguar Health filed a material event notification on Form 8-K, though the specific details of the announcement were not provided in the available summary text.
Feb 18
Institutional (13F) — Top 3
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Sbi Securities Co., Ltd. | 84 | $252 | New | Jun 2026 |
| 2 | Leonteq Securities Ag | 5 | $15 | New | Jun 2026 |
| 3 | International Assets Investment Management, Llc | 1 | $3 | New | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 2
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Total Market Index Fund | 19 | $67 | May 2026 |
| 2 | Fidelity Series Total Market Index Fund | 18 | $64 | May 2026 |
Valuation
Market Cap
$59K
Enterprise Value
$14.2M
P/E (TTM)
0.00x
Forward P/E
—
PEG Ratio
0.02x
P/B
—
P/S
0.00x
P/FCF
0.01x
EV/EBITDA
—
Shares Out
67K
Financials (TTM)
Revenue
$29.6M
Net Income
-$34.1M
EBITDA
-$37.9M
Free Cash Flow
$5.8M
Op Cash Flow
$5.8M
EPS Basic
$-803.95
EPS Diluted
$-708.72
EPS Forward
$-0.12
Gross Margin
85.1%
Op Margin
-86.3%
Net Margin
-115.4%
Balance Sheet
Total Assets
$38.3M
Total Liab.
$57.0M
Total Equity
-$18.7M
Cash
$968K
LT Debt
$15.1M
Book Value/Sh
$-8.01
Debt/Equity
-2.52x
Current Ratio
0.50
Quick Ratio
0.29
Returns & Growth
ROE
-248.6%
ROA
-139.8%
ROIC
-180.0%
Rev Growth YoY
-1.5%
EPS Growth YoY
+82.4%
Price Returns
2W
-8.4%
1M
-53.0%
3M
-76.6%
6M
-95.9%
12M
-98.8%
Technicals
52W High
$81.55
52W Low
$0.76
50d MA
$1.87
200d MA
$20.09
RSI (14)
43.80
ATR (14)
$0.10
Beta
0.29
Avg Volume
136K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$12.98
High
$12.98
Low
$12.98
Median
$12.98
Data updated apr 25, 2026 4:37pm
· Source: financialmodelingprep.com